Reuters logo
6 months ago
BRIEF-Immune Design receives orphan drug designation for G100 intratumoral product candidate
February 22, 2017 / 1:09 PM / 6 months ago

BRIEF-Immune Design receives orphan drug designation for G100 intratumoral product candidate

Feb 22 (Reuters) - Immune Design Corp

* Immune Design receives orphan drug designation for G100 intratumoral product candidate Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below